News Releases

These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.

May 14, 2018

Summary Toggle aTyr Pharma Announces First Quarter 2018 Operating Results, Program Prioritization and Corporate Restructuring

- Conference Call Today at 8:00 a.m. E.T./5:00 a.m. P.T. - SAN DIEGO , May 14, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced operating
May 8, 2018

Summary Toggle aTyr Pharma to Host Conference Call and Webcast of First Quarter 2018 Financial Results on May 14, 2018

SAN DIEGO , May 08, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it will report its first quarter financial results on Monday, May 14,
May 2, 2018

Summary Toggle aTyr Pharma Provides Mechanistic Update on Resokine Pathway at American Academy of Immunology Annual Meeting

– Identification of T Cell Immunomodulatory Domain in Resokine – SAN DIEGO , May 02, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced a poster
Mar 19, 2018

Summary Toggle aTyr Pharma Announces Fourth Quarter and Year-End 2017 Operating Results and Provides Corporate Update

- Conference Call Today at 2:00 p.m. PT / 5:00 p.m. ET - SAN DIEGO , March 19, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced operating
Mar 7, 2018

Summary Toggle aTyr Pharma to Host Conference Call and Webcast of Full Year 2017 Financial Results on March 19, 2018

SAN DIEGO , March 07, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it will report its year end 2017 financial results on Monday, March
Mar 1, 2018

Summary Toggle aTyr Pharma to Present at Two Upcoming Investor Conferences in March

SAN DIEGO , March 01, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced its participation at two investor conferences in March: A presentation at
Jan 4, 2018

Summary Toggle aTyr Pharma to Present at the 36th Annual J.P. Morgan Healthcare Conference

SAN DIEGO , Jan. 04, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that Sanjay Shukla , M.D., M.S., President and Chief Executive Officer,
Dec 21, 2017

Summary Toggle aTyr Pharma Announces Poster Presentation at ASCO-SITC Clinical Immuno-Oncology Symposium

aTyr’s ORCA program on-track to enter the clinic in 2019 SAN DIEGO , Dec. 21, 2017 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of immuno-modulatory protein therapeutics to treat patients suffering from rare, severe,
Dec 7, 2017

Summary Toggle aTyr Pharma to Participate at the BMO Prescriptions for Success Healthcare Conference

SAN DIEGO , Dec. 07, 2017 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of immuno-modulatory protein therapeutics to treat patients suffering from rare, severe, immune-mediated diseases, as well as various cancers, today
Nov 27, 2017

Summary Toggle aTyr Pharma Doses First Subjects in Phase 1 Trial of iMod.Fc (ATYR1923)

– Second Physiocrine-based therapeutic candidate enters the clinic – – Top-line data expected in 2Q 2018 – – iMod.Fc (ATYR1923) to target interstitial lung diseases with an immune component – SAN DIEGO , Nov. 27, 2017 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc.